Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients' prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of neutropenia and reducing its intensity as well as the risk of febrile neutropenia. There are short-and long-acting G-CSFs available these days. This paper is a review of the efficacy, toxicity and indications for short-and long-acting G-CSFs as indicated in the most recent studies.
Characteristic Weight
Clinical symptoms related to cancer or concomitant diseases • none or mild Pettengell et al. [6] , involving two groups of patients (with breast cancer and with lymphomas) indicated that chemotherapy may be delayed (≥ 4 days) in up to 34% of breast cancer patients, 54% of non-Hodgkin lymphoma (nHl) patients, and 40% of Hl patients. The dose was found to have been reduced (≥ 10%) in 14.2% of breast cancer patients, and in 33.3% of nHl patients.
The study reported RDi reduction of ≤ 85% in 20% of breast cancer patients and in 30% of patients with lymphomas. The main risk factors involved:
• eCoG performance status > 1
• age ≥ 65
• neutropenia with fever in the first cycle of chemotherapy.
it has been demonstrated that even RDi reduction of less than 10% compromises treatment outcomes, including patient survival [7] .
cOLONy stImULAtINg FActOrs
Granulocyte colony-stimulating factors (G-CSF) stimulate the proliferation and differentiation of progenitor cells and neutrophil precursor lines as well as prolong the half-life and improve phagocytic activity of neutrophils [8] .
Presently, there are two G-CSF types available on the market: the short-acting G-CSF, including filgrastim, tbo-filgrastim, filgrastim-sndz and lenograstim, and the pegylated long-acting one (pegfilgrastim and lipegfilgrastim).
Filgrastim was the first short-acting G-CSF in clinical practice. it is a recombinant methionyl human granulocyte colony-stimulating factor, produced by recombinant Dna technology in the Escherichia coli cells. it is chiefly eliminated via the kidneys, which is why it requires daily administration [9] . according to manufacturer recommendations, filgrastim should be administered once daily, subcutaneously or intravenously, dosed at 5 µg/kg body weight/24 h, to patients who receive cytotoxic drugs, and should be initiated no sooner than 24 hours after chemotherapy. Due to their mechanism of action and a short half-life, all short-acting G-CSF products require daily administration until the neutrophil count returns to normal (around 11 doses per one chemotherapy cycle) [1, 3, 4, 10, 11] .
in long-acting G-CSF preparations, plasma clearance has been limited thanks to the development of a recombinant human granulocyte colony-stimulating factor covalently conjugated to a particle of polyethylene glycol (PeG). The long-acting products are mainly eliminated by neutrophils, which renders their concentration high during neutropenia, followed by a gradual decrease as the neutrophil count continues to go up. That mod- 
UsINg g-csF IN AccOrDANcE WItH tHE gUIDELINEs
in line with their characteristics, G-CSF products should be used in order to shorten the duration and to reduce the incidence of • patient age > 65
• advanced underlying condition
• prior episodes of Fn
• no antibiotic prophylaxis
• malnutrition or poor performance status
• female sex
• liver, kidney or heart failure.
Risk assessment should be performed before each consecutive chemotherapy cycle. in the case of Fn and/or dose-reducing neutropenia following the previous chemotherapy cycle, the patient is burdened with a high risk, and secondary G-CSF prevention should be included in the subsequent cycle [1] [2] [3] [4] .
international literature contains relatively few findings on the therapeutic use of G-CSF. a meta-analysis from Cochrane's database, involving 1518 subjects from 13 studies, reported a shorter hospital stay and an increase in the neutrophil count, without improved survival, in patients receiving therapeutic G-CSF [14] . according to the nCCn guidelines, patients who develop Fn despite G-CSF prophylaxis should continue receiving the drug at the same dose.
However, extra G-CSF doses are not recommended to patients on long-acting G-CSF products. in a group with no prior G-CSF prevention, possible additional risk factors must be considered, including:
• age > 65
• sepsis
• prolonged (> 10 days) neutropenia < 100/µl
• pneumonia
• invasive fungal infection or other infections
• hospital stay
• prior FN episode.
according to the above mentioned principles, Fn risk should be assessed anew before each chemotherapy cycle [3] . it should be emphasised here that filgrastim and filgrastim-sndz are indicated for therapeutic use, while pegfilgrastim and lipegfilgrastim have only been studied in the context of preventative use [3] .
G-CSF is also used to mobilize the CD34+ stem cells. according to the nCCn guidelines [3] , short-acting G-CSF products (filgrastim, filgrastim-sndz and tbo-filgrastim) are indicated for CD34+ harvest, with the recommended dose of 10 µg/kg body weight/24 h sct. Based on the recent findings, though, single-dose long-acting products (pegfilgrastim) are equally efficacious [15] .
G-CSF may also be administered to accelerate regeneration following bone marrow transplantation. The nCCn guidelines [3] discuss the use of filgrastim and its derivatives starting from day 
DOsINg scHEDULE ADHErENcE
adherence, i.e. using G-CSF in line with the above mentioned guidelines is an important issue. Study results indicate that • 38.8% of lung cancer patients
• 59.4% of lymphoma patients • in the R-CHoP-14 group -14% of younger patients, and 19%
of elderly patients
• in the R-CHoP-21 group -as much as 61% of younger patients, and 47% of elderly patients.
older age was associated with a higher probability of G-CSF use [19] . an additional problem was found to be the duration of short-acting G-CSF product use, which was often insufficient.
in clinical trials [10, 11] dedicated to the comparable efficacy of pegfilgastrim and filgastrim, the latter was administered for 10-11 days. a similar finding was reported for a paediatric group (61 patients, including 29 treated with filgrastim and 32 treated with pegfilgrastim) after autologous bone marrow transplantation.
Filgrastim was found to be used for 7 up to 12 days [20] . However, studies comparing the efficacy of long-and short-acting G-CSF products indicate that a lower efficacy of the latter is often associated with an insufficient duration of their administration, i.e. from 3 to 7 days [12, 19] .
g-csF ImPAct ON tHE EFFIcAcy OF cHEmOtHErAPy
it has been demonstrated that G-CSF reduces the risk of febrile neutropenia, mortality related to infections, and the number of premature deaths [9, 21] .
Dose-reducing toxicity, including myelotoxicity, is one of the chief factors impacting the efficacy of anti-cancer treatment [1] [2] [3] [4] . intensified and prolonged neutropenia results in dose reduction and delayed administration of the consecutive cycles of chemotherapy, which in turn reduces its efficacy. emergence of G-CSF in the 1990s significantly improved patient prognosis [9, 21] . in a systematic review of 59 randomized studies, involving a total number of 25,000 patients with solid tumours and lymphomas, primary G-CSF prevention was found to reduce Fn risk, and improve the intensity of chemotherapy. moreover, the review revealed a considerable reduction of infection-related mortality risk and of early death during chemotherapy [21] .
Therefore, in line with the current guidelines, it is essential to initiate G-CSF prophylaxis as early as the first chemotherapy cycle.
introduction of hematopoietic growth factors made it possible to intensify treatment regimens, using standard doses of cytostatics in accelerated protocols, e.g. over periods shorter than 3 weeks 
EFFIcAcy AssEssmENt OF DIFFErENt g-csF tyPEs
G-CSF is a potent agent that releases mature neutrophils from bone marrow. a single dose (5 µg/kg body weight administered subcutaneously) results in a 5-fold increase in the neutrophil count of healthy persons within 12-24 hours, bringing it up from ca.
4,000/µl to 20,000/µl [23] . multiple use of G-CSF accelerates production of neutrophils and enhances their migration from bone marrow to peripheral blood [24] . Compared to placebo, as recent study results indicate, G-CSF significantly reduces Fn incidence in patients undergoing myelotoxic chemotherapy [9] [10] [11] 21] .
Together with the development of long-acting products, there came a question about their efficacy as compared to the short-acting ones. Presently, however, it is impossible to establish beyond any doubt what the guidelines should be as regards selection of the available G-CSF drugs. according to eSmo, short-acting G-CSF are equally efficacious provided that the dos-
The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia -the current state of knowledge M.A. Sobas, T. Wróbel ing schedule is appropriate, i.e. that they are administered no sooner than 24-72 h following chemotherapy, and for no fewer than 11 days. Those recommendations have been confirmed by two randomized double-blinded clinical studies involving stage ii-iV breast cancer patients undergoing myelosuppressive chemotherapy with doxorubicin and docetaxel. The studies demonstrate that long-acting G-CSF shows identical efficacy as the short-acting product on condition that the latter is administered from day 2 following chemotherapy until the level of anC ≥ 10,000/µl is reached, i.e. for around 10-11 days. in the first of the above mentioned studies, involving 157 patients, the mean duration of grade 4 neutropenia in those receiving pegfilgrastim at a single dose of 6 mg was 1.8 days, and in those on filgrastim it was 1.6 days, with the incidence of febrile neutropenia amounting to 13% and 20% respectively [11] . in the second study, involving 310 patients, pegfilgrastim was administered at a single dose of 100 µg/kg body weight. The mean duration of neutropenia in those on pegfilgrastim was 1.7 days, while in those receiving filgrastim it was 1.8 days, with the incidence of febrile neutropenia totalling 9% and 18% respectively [10] . 
g-csF tOXIcIty PrOFILE
The most frequent adverse event related to G-CSF is transient musculoskeletal pain, usually mild or moderate, and managed with standard painkillers [1] [2] [3] [4] 9] . no differences have been observed in terms of the pain frequency and intensity between the patients on long-acting and short-acting G-CSF products [1-4, 9, 13] .
individual publications also indicate that long-term administration of recombinant G-CSF may be associated with an increase in the risk of hematopoietic malignancies [27] . However, there is no unequivocal opinion to date on the increased risk of acute myeloblastic leukaemia (aml)/mDS in patients undergoing myelotoxic chemotherapy and G-CSF prophylaxis. Still, G-CSF should be avoided in mDS/aml [3] . it should be emphasised, though, according to the current guidelines, G-CSF should not be used after myelotoxic chemotherapy, followed by Fn risk exceeding 20% or ranging between 10% and 20% with additional risk factors, including:
• advanced age
• advanced stage of disease
• poor performance status
• malnutrition
• prior neutropenia.
Presently, there are no guidelines on the selection of short-or long-acting G-CSF products. Study results are not unequivocal in that matter. Pegylated long-acting agents appear to be more
The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia -the current state of knowledge M.A. Sobas, T. Wróbel convenient and easier to dose that the short-acting products, which are often administered at insufficient doses and not long enough to be fully effective. Hence, due to the higher adherence, long-acting G-CSF drugs have been reported as more efficacious in some studies. all in all, G-CSF products are well-tolerated and no differences in terms of their safety profile have been observed between the short-and long-acting ones.
What is most essential is that G-CSF drugs should be administered in accordance with their indications, i.e. to prevent neutropenia and Fn in high-risk patients after myeloablative chemotherapy, beginning from the very first treatment cycle. Thanks to such prophylaxis, the patient's quality of life may be improved, and the efficacy of anti-cancer treatment may be maximized.
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